Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $4.12.
A number of research analysts have recently issued reports on SNSS shares. ValuEngine raised Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 15th. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Tuesday, May 8th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $4.00 price objective on shares of Sunesis Pharmaceuticals in a report on Thursday, March 8th.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in Sunesis Pharmaceuticals by 38.4% during the first quarter. Wells Fargo & Company MN now owns 64,367 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 17,853 shares during the period. Spark Investment Management LLC acquired a new position in Sunesis Pharmaceuticals during the first quarter worth $204,000. Millennium Management LLC grew its holdings in Sunesis Pharmaceuticals by 594.4% during the first quarter. Millennium Management LLC now owns 106,599 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 91,248 shares during the period. Geode Capital Management LLC grew its holdings in Sunesis Pharmaceuticals by 105.2% during the fourth quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after acquiring an additional 64,343 shares during the period. Finally, BlackRock Inc. grew its holdings in Sunesis Pharmaceuticals by 9.5% during the fourth quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 11,351 shares during the period. 52.23% of the stock is currently owned by hedge funds and other institutional investors.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. The company had revenue of $0.24 million during the quarter. analysts expect that Sunesis Pharmaceuticals will post -0.92 earnings per share for the current fiscal year.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.